Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Christina Stoller

Internal Medicine Moline, IL Nurse Practitioner

NPI 1366172645 CMS profile 11361712

550 30Th Ave Ste 12, Moline, IL 61265

Open in the dashboard

General payments

$4,525

237 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christina Stoller of Moline, IL is reported in the CMS Open Payments database as having received $4,525 across 237 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,995 110
2024 General $1,483 72
2023 General $922 47
2022 General $124 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christina Stoller
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Christina Stoller were reported at $1,995. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Christina Stoller Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $124 $141 $42–$496 $149
2023 $922 $149 $45–$519 $160
2024 $1,483 $154 $47–$537 $164
2025 $1,995 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $1,027 41 payments
  2. AbbVie, Inc. $352 21 payments
  3. GlaxoSmithKline, LLC. $345 21 payments
  4. Novo Nordisk Inc $286 17 payments
  5. Pfizer Inc. $226 15 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $213 13 payments
  7. Regeneron Healthcare Solutions, Inc. $206 7 payments
  8. Lilly USA, LLC $195 12 payments
  9. Teva Pharmaceuticals USA, Inc. $183 11 payments
  10. Exact Sciences Corporation $163 10 payments
  11. Other $1,328 69 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,299 234 payments
  2. Education $226 3 payments
Products named General payments · program years 2022–2025
  1. FARXIGA $481 21 payments
  2. FASENRA $376 11 payments
  3. AIRSUPRA $311 6 payments
  4. TRELEGY ELLIPTA $286 15 payments
  5. Ozempic $272 16 payments
  6. DUPIXENT $206 7 payments
  7. QULIPTA $194 9 payments
  8. UBRELVY $191 9 payments
  9. Austedo XR $183 11 payments
  10. RYBELSUS $153 10 payments
  11. Other $3,141 172 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 88 drugs

Part D claims

3,188

Median for Internal Medicine: 777

Drug cost

$327,626

Median for Internal Medicine: $73,373

Branded share of claims

21.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 39 $45,313
Jardiance Empagliflozin Brand 32 $40,888
Eliquis Apixaban Brand 49 $39,592
Ozempic Semaglutide Brand 26 $34,405
Rybelsus Semaglutide Brand 15 $29,161
Spiriva Respimat Tiotropium Bromide Brand 12 $18,268
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 13 $17,544
Linzess Linaclotide Brand 18 $17,143
Zenpep Lipase/Protease/Amylase Brand 17 $15,022
Mounjaro Tirzepatide Brand 13 $14,040

The 10 drugs with the highest cost, of 88 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $185
  • GENZYME CORPORATION $20
$205 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $114
$114 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $85
$85 12 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $84
$84 39 —
Ozempic
  • Novo Nordisk Inc $80
$80 26 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

237 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record